Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00228-020-03008-6.pdf
Reference8 articles.
1. Heck J, Stichtenoth DO, Mettin R, Jöckel J, Bickel C, Krichevsky B (2020) Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature [published online ahead of print, 2020 Aug 6]. Eur J Clin Pharmacol 1-4
2. Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. Lancet. 395(10236):1569–1578
3. Beigel JH, Tomashek KM, Dodd LE, et al (2020) Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print, 2020 May 22]. N Engl J Med. NEJMoa2007764
4. Goldman JD, Lye DCB, Hui DS et al (2020) Remdesivir for 5 or 10 days in patients with severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. https://doi.org/10.1056/NEJMoa2015301
5. Spinner CD, Gottlieb RL, Criner GJ, et al. (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A Randomized Clinical Trial. JAMA. 324(11):1048–1057
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09
2. Pharmacovigilance Concept Knowledge, Perspectives and Attitudes: A Cross-Sectional Study Among Community Pharmacists;INQUIRY: The Journal of Health Care Organization, Provision, and Financing;2024-01
3. A Critical Assessment of Remdesivir;Current Drug Therapy;2023-10-31
4. Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review;BMJ Medicine;2023-08
5. Reporting of harms in clinical trials of esketamine in depression: a systematic review;Psychological Medicine;2023-04-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3